Resumen
Introduction: Primary Cutaneous T-cell Lymphomas represent the most common subtype of Cutaneous Lymphomas and are characterized by clonal proliferation of skin-homing T lymphocytes. Their clinical presentation is often heterogeneous and may mimic benign inflammatory dermatoses. Objective: We report the case of a 21-year-old male presenting with disseminated macular dermatosis associated with pancytopenia. Results: Histopathology revealed epidermotropism with atypical lymphocytic infiltration. Immunohistochemistry showed CD3 (+), CD4 (+), CD8 (+), CD5 (+), and CD20 (−), confirming T-cell lineage. Conclusion: This case highlights the importance of clinicopathologic correlation in persistent atypical cutaneous lesions in young patients.
Citas
1. Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-14. doi:10.1182/blood-2018-11-881268.
2. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-85. doi:10.1182/blood-2004-09-3502.
3. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053-63. doi:10.1016/j.jaad.2005.08.057.
4. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064-73. doi:10.1182/blood-2008-10-184168.
5. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70(2):205.e1-22. doi:10.1016/j.jaad.2013.07.049.
6. Milette F. Review: Skin Lymphoma. The Illustrated Guide, 4th edition, by Lorenzo Cerroni. Dermatol Pract Concept. 2014;4(4):79-80. doi:10.5826/dpc.0404a17.
7. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720-48. doi:10.1038/s41375-022-01620-2.
8. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598-607. doi:10.1200/JCO.2010.32.0630.
9. Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for treatment of mycosis fungoides/Sézary syndrome – 2021 update. Eur J Cancer. 2021;156:74-93. doi:10.1016/j.ejca.2021.06.017.
10. Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555-66. doi:10.1016/S0140-6736(17)31266-7.
11. Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192-204. doi:10.1016/S1470-2045(18)30379-6.
12. Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T-cell lymphoma. Nat Genet. 2015;47(9):1011-9. doi:10.1038/ng.3356.
Copyright
License
Copyright (c) 2026 María José Polanco García, Vilma Renée García Benítez, Alejandra Maria Gonzalez Orellana
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish in this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License 4.0 (CC BY-NC_SA 4.0) that indicates: a) It is allowed that others share the work, with an acknowledgement of the work's authorship and initial publication in this journal, b) The work may not be used for commercial purposes, c) If it's remixed, transformed, or built upon the material, one must distribute the contributions under the same license as the original
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository, website or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
